VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma

• Published in: Biomolecules & Biomedicine Vol. 23; no. 1; pp. 26 - 36
• Main Authors: Todorovic, Lidija, Stanojevic, Boban
• Format: Journal Article
• Language: English
• Published: Bosnia and Herzegovina Association of Basic Medical Sciences 01.02.2023; Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
• Subjects: biomarker; Biomarkers; Carcinoma, Papillary - diagnosis; Complications and side effects; Development and progression; Genes, Tumor Suppressor; Genetic aspects; Genetic markers; Health aspects; Humans; Papillary thyroid cancer; Physiological aspects; PTC; Review; Risk factors; risk stratification; Thyroid cancer; Thyroid Cancer, Papillary - diagnosis; Thyroid Neoplasms - diagnosis; tumor suppressor; Tumor suppressor genes; VHL; Von Hippel-Lindau disease; Von Hippel-Lindau Tumor Suppressor Protein - genetics; Serbia
• ISSN: 1512-8601; 2831-0896; 2831-090X; 1840-4812; 2831-090X
• DOI: 10.17305/bjbms.2022.7850

Papillary thyroid carcinoma (PTC) is the most common type of endocrine cancer, with an increasing incidence worldwide. The treatment of PTC is currently the subject of clinical controversy, making it critically important to identify molecular markers that would help improve the risk stratification of PTC patients and optimize the therapeutic approach. The VHL tumor suppressor gene has been implicated in tumorigenesis of various types of carcinoma and linked with their aggressive biological behavior. The role of VHL in the origin and development of PTC has only recently begun to be revealed. In this narrative review we attempt to summarize the existing knowledge that implicates VHL in PTC pathogenesis and to outline its potential significance as a candidate molecular biomarker for the grouping of PTC patients into high and low risk groups.